Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments
Abstract Background Aim was to evaluate the efficacy and tolerability of a moxifloxacin-containing second-line triple regimen in patients whose previous Helicobacter pylori eradication treatment failed. Methods Prospective multicentre study including patients in whom a triple therapy or a non-bismut...
Gespeichert in:
| Veröffentlicht in: | Digestive and liver disease 2015-02, Vol.47 (2), p.108-113 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 113 |
|---|---|
| container_issue | 2 |
| container_start_page | 108 |
| container_title | Digestive and liver disease |
| container_volume | 47 |
| creator | Gisbert, Javier P Romano, Marco Molina-Infante, Javier Lucendo, Alfredo J Medina, Enrique Modolell, Inés Rodríguez-Tellez, Manuel Gomez, Blas Barrio, Jesús Perona, Monica Ortuño, Juan Ariño, Inés Domínguez-Muñoz, Juan Enrique Perez-Aisa, Ángeles Bermejo, Fernando Domínguez, Jose Luis Almela, Pedro Gomez-Camarero, Judith Millastre, Judith Martin-Noguerol, Elisa Gravina, Antonietta G Martorano, Marco Miranda, Agnese Federico, Alessandro Fernandez-Bermejo, Miguel Angueira, Teresa Ferrer-Barcelo, Luis Fernández, Nuria Marín, Alicia C McNicholl, Adrián G |
| description | Abstract Background Aim was to evaluate the efficacy and tolerability of a moxifloxacin-containing second-line triple regimen in patients whose previous Helicobacter pylori eradication treatment failed. Methods Prospective multicentre study including patients in whom a triple therapy or a non-bismuth-quadruple-therapy failed. Moxifloxacin (400 mg qd), amoxicillin (1 g bid), and esomeprazole (40 mg bid) were prescribed for 14 days. Eradication was confirmed by13 C-urea-breath-test. Compliance was determined through questioning and recovery of empty medication envelopes. Results 250 patients were consecutively included (mean age 48 ± 15 years, 11% with ulcer). Previous (failed) therapy included: standard triple ( n = 179), sequential ( n = 27), and concomitant ( n = 44); 97% of patients took all medications, 4 were lost to follow-up. Intention-to-treat and per-protocol eradication rates were 82.4% (95% CI, 77–87%) and 85.7% (95% CI, 81–90%). Cure rates were similar independently of diagnosis (ulcer, 77%; dyspepsia, 82%) and previous treatment (standard triple, 83%; sequential, 89%; concomitant, 77%). At multivariate analysis, only age was associated with eradication (OR = 0.957; 95% CI, 0.933–0.981). Adverse events were reported in 25.2% of patients: diarrhoea (9.6%), abdominal pain (9.6%), and nausea (9.2%). Conclusion 14-day moxifloxacin-containing triple therapy is an effective and safe second-line strategy in patients whose previous standard triple therapy or non-bismuth quadruple (sequential or concomitant) therapy has failed, providing a simple alternative to bismuth quadruple regimen. |
| doi_str_mv | 10.1016/j.dld.2014.10.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1652408161</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1590865814007543</els_id><sourcerecordid>1652408161</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-75ba9a51068d5b51c2e9191dfd416311493019ab079ccc348f36f6b4ee91ddbd3</originalsourceid><addsrcrecordid>eNp9UsFu1TAQjBCIlsIHcEE-cmge3iR2EiEhoQooUiUOlLPl2BviV8dObYf2fQ2_iqPXcuDAyevdmVntzhbFa6A7oMDf7Xfa6l1Focn_HaX9k-IUurYra8arpzlmPS07zrqT4kWMe0or4Iw-L04q1rCmpfy0-H1958s7xJtzMpmfU6l9RLIEn7wjyzovxLjJDCb5cE5mf29G6--lMo6kYBaL5BKtUX6QKmEgy8H6YEiaMMjlQOS4JUdp7BqQ-JHEJJ2WQT-SfSDOu3IwcV7TRG5XqcO6FVJAmWZ0Kb4sno3SRnz18J4VPz5_ur64LK--ffl68fGqVA3tUtmyQfaSAeWdZgMDVWEPPehRN8BrgKavKfRyoG2vlKqbbqz5yIcGM0zrQddnxdujbp79dsWYxGyiQmulQ79GkRdX5U7AIUPhCFXBxxhwFEswswwHAVRsvoi9yL6IzZctlX3JnDcP8uswo_7LeDQiA94fAZiH_GUwiKgMOoXaBFRJaG_-K__hH7ayxhkl7Q0eMO79GlzengARK0HF9-0wtruAhtKWNXX9B2vytr0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1652408161</pqid></control><display><type>article</type><title>Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Gisbert, Javier P ; Romano, Marco ; Molina-Infante, Javier ; Lucendo, Alfredo J ; Medina, Enrique ; Modolell, Inés ; Rodríguez-Tellez, Manuel ; Gomez, Blas ; Barrio, Jesús ; Perona, Monica ; Ortuño, Juan ; Ariño, Inés ; Domínguez-Muñoz, Juan Enrique ; Perez-Aisa, Ángeles ; Bermejo, Fernando ; Domínguez, Jose Luis ; Almela, Pedro ; Gomez-Camarero, Judith ; Millastre, Judith ; Martin-Noguerol, Elisa ; Gravina, Antonietta G ; Martorano, Marco ; Miranda, Agnese ; Federico, Alessandro ; Fernandez-Bermejo, Miguel ; Angueira, Teresa ; Ferrer-Barcelo, Luis ; Fernández, Nuria ; Marín, Alicia C ; McNicholl, Adrián G</creator><creatorcontrib>Gisbert, Javier P ; Romano, Marco ; Molina-Infante, Javier ; Lucendo, Alfredo J ; Medina, Enrique ; Modolell, Inés ; Rodríguez-Tellez, Manuel ; Gomez, Blas ; Barrio, Jesús ; Perona, Monica ; Ortuño, Juan ; Ariño, Inés ; Domínguez-Muñoz, Juan Enrique ; Perez-Aisa, Ángeles ; Bermejo, Fernando ; Domínguez, Jose Luis ; Almela, Pedro ; Gomez-Camarero, Judith ; Millastre, Judith ; Martin-Noguerol, Elisa ; Gravina, Antonietta G ; Martorano, Marco ; Miranda, Agnese ; Federico, Alessandro ; Fernandez-Bermejo, Miguel ; Angueira, Teresa ; Ferrer-Barcelo, Luis ; Fernández, Nuria ; Marín, Alicia C ; McNicholl, Adrián G</creatorcontrib><description>Abstract Background Aim was to evaluate the efficacy and tolerability of a moxifloxacin-containing second-line triple regimen in patients whose previous Helicobacter pylori eradication treatment failed. Methods Prospective multicentre study including patients in whom a triple therapy or a non-bismuth-quadruple-therapy failed. Moxifloxacin (400 mg qd), amoxicillin (1 g bid), and esomeprazole (40 mg bid) were prescribed for 14 days. Eradication was confirmed by13 C-urea-breath-test. Compliance was determined through questioning and recovery of empty medication envelopes. Results 250 patients were consecutively included (mean age 48 ± 15 years, 11% with ulcer). Previous (failed) therapy included: standard triple ( n = 179), sequential ( n = 27), and concomitant ( n = 44); 97% of patients took all medications, 4 were lost to follow-up. Intention-to-treat and per-protocol eradication rates were 82.4% (95% CI, 77–87%) and 85.7% (95% CI, 81–90%). Cure rates were similar independently of diagnosis (ulcer, 77%; dyspepsia, 82%) and previous treatment (standard triple, 83%; sequential, 89%; concomitant, 77%). At multivariate analysis, only age was associated with eradication (OR = 0.957; 95% CI, 0.933–0.981). Adverse events were reported in 25.2% of patients: diarrhoea (9.6%), abdominal pain (9.6%), and nausea (9.2%). Conclusion 14-day moxifloxacin-containing triple therapy is an effective and safe second-line strategy in patients whose previous standard triple therapy or non-bismuth quadruple (sequential or concomitant) therapy has failed, providing a simple alternative to bismuth quadruple regimen.</description><identifier>ISSN: 1590-8658</identifier><identifier>EISSN: 1878-3562</identifier><identifier>DOI: 10.1016/j.dld.2014.10.009</identifier><identifier>PMID: 25454706</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adult ; Amoxicillin - therapeutic use ; Anti-Bacterial Agents - therapeutic use ; Breath Tests ; Cohort Studies ; Drug Therapy, Combination ; Eradication ; Esomeprazole - therapeutic use ; Failure ; Female ; Fluoroquinolones - therapeutic use ; Gastroenterology and Hepatology ; Helicobacter Infections - drug therapy ; Helicobacter pylori ; Humans ; Levofloxacin ; Male ; Middle Aged ; Moxifloxacin ; Prospective Studies ; Proton Pump Inhibitors - therapeutic use ; Quinolones ; Rescue ; Retreatment ; Therapy ; Treatment Failure ; Treatment Outcome ; Urea - analysis</subject><ispartof>Digestive and liver disease, 2015-02, Vol.47 (2), p.108-113</ispartof><rights>Editrice Gastroenterologica Italiana S.r.l.</rights><rights>2014 Editrice Gastroenterologica Italiana S.r.l.</rights><rights>Copyright © 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-75ba9a51068d5b51c2e9191dfd416311493019ab079ccc348f36f6b4ee91ddbd3</citedby><cites>FETCH-LOGICAL-c408t-75ba9a51068d5b51c2e9191dfd416311493019ab079ccc348f36f6b4ee91ddbd3</cites><orcidid>0000-0003-2090-3445</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1590865814007543$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25454706$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gisbert, Javier P</creatorcontrib><creatorcontrib>Romano, Marco</creatorcontrib><creatorcontrib>Molina-Infante, Javier</creatorcontrib><creatorcontrib>Lucendo, Alfredo J</creatorcontrib><creatorcontrib>Medina, Enrique</creatorcontrib><creatorcontrib>Modolell, Inés</creatorcontrib><creatorcontrib>Rodríguez-Tellez, Manuel</creatorcontrib><creatorcontrib>Gomez, Blas</creatorcontrib><creatorcontrib>Barrio, Jesús</creatorcontrib><creatorcontrib>Perona, Monica</creatorcontrib><creatorcontrib>Ortuño, Juan</creatorcontrib><creatorcontrib>Ariño, Inés</creatorcontrib><creatorcontrib>Domínguez-Muñoz, Juan Enrique</creatorcontrib><creatorcontrib>Perez-Aisa, Ángeles</creatorcontrib><creatorcontrib>Bermejo, Fernando</creatorcontrib><creatorcontrib>Domínguez, Jose Luis</creatorcontrib><creatorcontrib>Almela, Pedro</creatorcontrib><creatorcontrib>Gomez-Camarero, Judith</creatorcontrib><creatorcontrib>Millastre, Judith</creatorcontrib><creatorcontrib>Martin-Noguerol, Elisa</creatorcontrib><creatorcontrib>Gravina, Antonietta G</creatorcontrib><creatorcontrib>Martorano, Marco</creatorcontrib><creatorcontrib>Miranda, Agnese</creatorcontrib><creatorcontrib>Federico, Alessandro</creatorcontrib><creatorcontrib>Fernandez-Bermejo, Miguel</creatorcontrib><creatorcontrib>Angueira, Teresa</creatorcontrib><creatorcontrib>Ferrer-Barcelo, Luis</creatorcontrib><creatorcontrib>Fernández, Nuria</creatorcontrib><creatorcontrib>Marín, Alicia C</creatorcontrib><creatorcontrib>McNicholl, Adrián G</creatorcontrib><title>Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments</title><title>Digestive and liver disease</title><addtitle>Dig Liver Dis</addtitle><description>Abstract Background Aim was to evaluate the efficacy and tolerability of a moxifloxacin-containing second-line triple regimen in patients whose previous Helicobacter pylori eradication treatment failed. Methods Prospective multicentre study including patients in whom a triple therapy or a non-bismuth-quadruple-therapy failed. Moxifloxacin (400 mg qd), amoxicillin (1 g bid), and esomeprazole (40 mg bid) were prescribed for 14 days. Eradication was confirmed by13 C-urea-breath-test. Compliance was determined through questioning and recovery of empty medication envelopes. Results 250 patients were consecutively included (mean age 48 ± 15 years, 11% with ulcer). Previous (failed) therapy included: standard triple ( n = 179), sequential ( n = 27), and concomitant ( n = 44); 97% of patients took all medications, 4 were lost to follow-up. Intention-to-treat and per-protocol eradication rates were 82.4% (95% CI, 77–87%) and 85.7% (95% CI, 81–90%). Cure rates were similar independently of diagnosis (ulcer, 77%; dyspepsia, 82%) and previous treatment (standard triple, 83%; sequential, 89%; concomitant, 77%). At multivariate analysis, only age was associated with eradication (OR = 0.957; 95% CI, 0.933–0.981). Adverse events were reported in 25.2% of patients: diarrhoea (9.6%), abdominal pain (9.6%), and nausea (9.2%). Conclusion 14-day moxifloxacin-containing triple therapy is an effective and safe second-line strategy in patients whose previous standard triple therapy or non-bismuth quadruple (sequential or concomitant) therapy has failed, providing a simple alternative to bismuth quadruple regimen.</description><subject>Adult</subject><subject>Amoxicillin - therapeutic use</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Breath Tests</subject><subject>Cohort Studies</subject><subject>Drug Therapy, Combination</subject><subject>Eradication</subject><subject>Esomeprazole - therapeutic use</subject><subject>Failure</subject><subject>Female</subject><subject>Fluoroquinolones - therapeutic use</subject><subject>Gastroenterology and Hepatology</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter pylori</subject><subject>Humans</subject><subject>Levofloxacin</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Moxifloxacin</subject><subject>Prospective Studies</subject><subject>Proton Pump Inhibitors - therapeutic use</subject><subject>Quinolones</subject><subject>Rescue</subject><subject>Retreatment</subject><subject>Therapy</subject><subject>Treatment Failure</subject><subject>Treatment Outcome</subject><subject>Urea - analysis</subject><issn>1590-8658</issn><issn>1878-3562</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UsFu1TAQjBCIlsIHcEE-cmge3iR2EiEhoQooUiUOlLPl2BviV8dObYf2fQ2_iqPXcuDAyevdmVntzhbFa6A7oMDf7Xfa6l1Focn_HaX9k-IUurYra8arpzlmPS07zrqT4kWMe0or4Iw-L04q1rCmpfy0-H1958s7xJtzMpmfU6l9RLIEn7wjyzovxLjJDCb5cE5mf29G6--lMo6kYBaL5BKtUX6QKmEgy8H6YEiaMMjlQOS4JUdp7BqQ-JHEJJ2WQT-SfSDOu3IwcV7TRG5XqcO6FVJAmWZ0Kb4sno3SRnz18J4VPz5_ur64LK--ffl68fGqVA3tUtmyQfaSAeWdZgMDVWEPPehRN8BrgKavKfRyoG2vlKqbbqz5yIcGM0zrQddnxdujbp79dsWYxGyiQmulQ79GkRdX5U7AIUPhCFXBxxhwFEswswwHAVRsvoi9yL6IzZctlX3JnDcP8uswo_7LeDQiA94fAZiH_GUwiKgMOoXaBFRJaG_-K__hH7ayxhkl7Q0eMO79GlzengARK0HF9-0wtruAhtKWNXX9B2vytr0</recordid><startdate>20150201</startdate><enddate>20150201</enddate><creator>Gisbert, Javier P</creator><creator>Romano, Marco</creator><creator>Molina-Infante, Javier</creator><creator>Lucendo, Alfredo J</creator><creator>Medina, Enrique</creator><creator>Modolell, Inés</creator><creator>Rodríguez-Tellez, Manuel</creator><creator>Gomez, Blas</creator><creator>Barrio, Jesús</creator><creator>Perona, Monica</creator><creator>Ortuño, Juan</creator><creator>Ariño, Inés</creator><creator>Domínguez-Muñoz, Juan Enrique</creator><creator>Perez-Aisa, Ángeles</creator><creator>Bermejo, Fernando</creator><creator>Domínguez, Jose Luis</creator><creator>Almela, Pedro</creator><creator>Gomez-Camarero, Judith</creator><creator>Millastre, Judith</creator><creator>Martin-Noguerol, Elisa</creator><creator>Gravina, Antonietta G</creator><creator>Martorano, Marco</creator><creator>Miranda, Agnese</creator><creator>Federico, Alessandro</creator><creator>Fernandez-Bermejo, Miguel</creator><creator>Angueira, Teresa</creator><creator>Ferrer-Barcelo, Luis</creator><creator>Fernández, Nuria</creator><creator>Marín, Alicia C</creator><creator>McNicholl, Adrián G</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2090-3445</orcidid></search><sort><creationdate>20150201</creationdate><title>Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments</title><author>Gisbert, Javier P ; Romano, Marco ; Molina-Infante, Javier ; Lucendo, Alfredo J ; Medina, Enrique ; Modolell, Inés ; Rodríguez-Tellez, Manuel ; Gomez, Blas ; Barrio, Jesús ; Perona, Monica ; Ortuño, Juan ; Ariño, Inés ; Domínguez-Muñoz, Juan Enrique ; Perez-Aisa, Ángeles ; Bermejo, Fernando ; Domínguez, Jose Luis ; Almela, Pedro ; Gomez-Camarero, Judith ; Millastre, Judith ; Martin-Noguerol, Elisa ; Gravina, Antonietta G ; Martorano, Marco ; Miranda, Agnese ; Federico, Alessandro ; Fernandez-Bermejo, Miguel ; Angueira, Teresa ; Ferrer-Barcelo, Luis ; Fernández, Nuria ; Marín, Alicia C ; McNicholl, Adrián G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-75ba9a51068d5b51c2e9191dfd416311493019ab079ccc348f36f6b4ee91ddbd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Amoxicillin - therapeutic use</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Breath Tests</topic><topic>Cohort Studies</topic><topic>Drug Therapy, Combination</topic><topic>Eradication</topic><topic>Esomeprazole - therapeutic use</topic><topic>Failure</topic><topic>Female</topic><topic>Fluoroquinolones - therapeutic use</topic><topic>Gastroenterology and Hepatology</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter pylori</topic><topic>Humans</topic><topic>Levofloxacin</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Moxifloxacin</topic><topic>Prospective Studies</topic><topic>Proton Pump Inhibitors - therapeutic use</topic><topic>Quinolones</topic><topic>Rescue</topic><topic>Retreatment</topic><topic>Therapy</topic><topic>Treatment Failure</topic><topic>Treatment Outcome</topic><topic>Urea - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gisbert, Javier P</creatorcontrib><creatorcontrib>Romano, Marco</creatorcontrib><creatorcontrib>Molina-Infante, Javier</creatorcontrib><creatorcontrib>Lucendo, Alfredo J</creatorcontrib><creatorcontrib>Medina, Enrique</creatorcontrib><creatorcontrib>Modolell, Inés</creatorcontrib><creatorcontrib>Rodríguez-Tellez, Manuel</creatorcontrib><creatorcontrib>Gomez, Blas</creatorcontrib><creatorcontrib>Barrio, Jesús</creatorcontrib><creatorcontrib>Perona, Monica</creatorcontrib><creatorcontrib>Ortuño, Juan</creatorcontrib><creatorcontrib>Ariño, Inés</creatorcontrib><creatorcontrib>Domínguez-Muñoz, Juan Enrique</creatorcontrib><creatorcontrib>Perez-Aisa, Ángeles</creatorcontrib><creatorcontrib>Bermejo, Fernando</creatorcontrib><creatorcontrib>Domínguez, Jose Luis</creatorcontrib><creatorcontrib>Almela, Pedro</creatorcontrib><creatorcontrib>Gomez-Camarero, Judith</creatorcontrib><creatorcontrib>Millastre, Judith</creatorcontrib><creatorcontrib>Martin-Noguerol, Elisa</creatorcontrib><creatorcontrib>Gravina, Antonietta G</creatorcontrib><creatorcontrib>Martorano, Marco</creatorcontrib><creatorcontrib>Miranda, Agnese</creatorcontrib><creatorcontrib>Federico, Alessandro</creatorcontrib><creatorcontrib>Fernandez-Bermejo, Miguel</creatorcontrib><creatorcontrib>Angueira, Teresa</creatorcontrib><creatorcontrib>Ferrer-Barcelo, Luis</creatorcontrib><creatorcontrib>Fernández, Nuria</creatorcontrib><creatorcontrib>Marín, Alicia C</creatorcontrib><creatorcontrib>McNicholl, Adrián G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive and liver disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gisbert, Javier P</au><au>Romano, Marco</au><au>Molina-Infante, Javier</au><au>Lucendo, Alfredo J</au><au>Medina, Enrique</au><au>Modolell, Inés</au><au>Rodríguez-Tellez, Manuel</au><au>Gomez, Blas</au><au>Barrio, Jesús</au><au>Perona, Monica</au><au>Ortuño, Juan</au><au>Ariño, Inés</au><au>Domínguez-Muñoz, Juan Enrique</au><au>Perez-Aisa, Ángeles</au><au>Bermejo, Fernando</au><au>Domínguez, Jose Luis</au><au>Almela, Pedro</au><au>Gomez-Camarero, Judith</au><au>Millastre, Judith</au><au>Martin-Noguerol, Elisa</au><au>Gravina, Antonietta G</au><au>Martorano, Marco</au><au>Miranda, Agnese</au><au>Federico, Alessandro</au><au>Fernandez-Bermejo, Miguel</au><au>Angueira, Teresa</au><au>Ferrer-Barcelo, Luis</au><au>Fernández, Nuria</au><au>Marín, Alicia C</au><au>McNicholl, Adrián G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments</atitle><jtitle>Digestive and liver disease</jtitle><addtitle>Dig Liver Dis</addtitle><date>2015-02-01</date><risdate>2015</risdate><volume>47</volume><issue>2</issue><spage>108</spage><epage>113</epage><pages>108-113</pages><issn>1590-8658</issn><eissn>1878-3562</eissn><abstract>Abstract Background Aim was to evaluate the efficacy and tolerability of a moxifloxacin-containing second-line triple regimen in patients whose previous Helicobacter pylori eradication treatment failed. Methods Prospective multicentre study including patients in whom a triple therapy or a non-bismuth-quadruple-therapy failed. Moxifloxacin (400 mg qd), amoxicillin (1 g bid), and esomeprazole (40 mg bid) were prescribed for 14 days. Eradication was confirmed by13 C-urea-breath-test. Compliance was determined through questioning and recovery of empty medication envelopes. Results 250 patients were consecutively included (mean age 48 ± 15 years, 11% with ulcer). Previous (failed) therapy included: standard triple ( n = 179), sequential ( n = 27), and concomitant ( n = 44); 97% of patients took all medications, 4 were lost to follow-up. Intention-to-treat and per-protocol eradication rates were 82.4% (95% CI, 77–87%) and 85.7% (95% CI, 81–90%). Cure rates were similar independently of diagnosis (ulcer, 77%; dyspepsia, 82%) and previous treatment (standard triple, 83%; sequential, 89%; concomitant, 77%). At multivariate analysis, only age was associated with eradication (OR = 0.957; 95% CI, 0.933–0.981). Adverse events were reported in 25.2% of patients: diarrhoea (9.6%), abdominal pain (9.6%), and nausea (9.2%). Conclusion 14-day moxifloxacin-containing triple therapy is an effective and safe second-line strategy in patients whose previous standard triple therapy or non-bismuth quadruple (sequential or concomitant) therapy has failed, providing a simple alternative to bismuth quadruple regimen.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>25454706</pmid><doi>10.1016/j.dld.2014.10.009</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-2090-3445</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1590-8658 |
| ispartof | Digestive and liver disease, 2015-02, Vol.47 (2), p.108-113 |
| issn | 1590-8658 1878-3562 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1652408161 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Amoxicillin - therapeutic use Anti-Bacterial Agents - therapeutic use Breath Tests Cohort Studies Drug Therapy, Combination Eradication Esomeprazole - therapeutic use Failure Female Fluoroquinolones - therapeutic use Gastroenterology and Hepatology Helicobacter Infections - drug therapy Helicobacter pylori Humans Levofloxacin Male Middle Aged Moxifloxacin Prospective Studies Proton Pump Inhibitors - therapeutic use Quinolones Rescue Retreatment Therapy Treatment Failure Treatment Outcome Urea - analysis |
| title | Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T09%3A23%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Two-week,%20high-dose%20proton%20pump%20inhibitor,%20moxifloxacin%20triple%20Helicobacter%20pylori%20therapy%20after%20failure%20of%20standard%20triple%20or%20non-bismuth%20quadruple%20treatments&rft.jtitle=Digestive%20and%20liver%20disease&rft.au=Gisbert,%20Javier%20P&rft.date=2015-02-01&rft.volume=47&rft.issue=2&rft.spage=108&rft.epage=113&rft.pages=108-113&rft.issn=1590-8658&rft.eissn=1878-3562&rft_id=info:doi/10.1016/j.dld.2014.10.009&rft_dat=%3Cproquest_cross%3E1652408161%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1652408161&rft_id=info:pmid/25454706&rft_els_id=1_s2_0_S1590865814007543&rfr_iscdi=true |